Vistagen Therapeutics, Inc.
VTGNDrugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
23dMarket Overview
Stock performance and key metrics
1 upcoming, 2 past
How VTGN's past catalysts played out
PH94B Nasal Spray
Social Anxiety Disorder
Fasedienol Nasal Spray
Social Anxiety Disorder (SAD)
AV-101
Major Depressive Disorder
PH94B
Adjustment Disorder With Anxious Mood
Fasedienol Nasal Spray - Fasedienol Nasal Spray
Social Anxiety Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PH94B Nasal Spray | Phase 3 | Social Anxiety Disorder | - | - |
Fasedienol Nasal Spray | Phase 3 | Social Anxiety Disorder (SAD) | - | - |
AV-101 | Phase 2 | Major Depressive Disorder | - | - |
PH94B | Phase 2 | Adjustment Disorder With Anxious Mood | - | - |
Fasedienol Nasal Spray - Fasedienol Nasal Spray | Phase 2 | Social Anxiety Disorder | - | - |
Social Anxiety Disorder
3 drugs in this indication
Major Depressive Disorder
1 drug in this indication
Adjustment Disorder With Anxious Mood
1 drug in this indication
Social Anxiety Disorder (SAD)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Vistagen Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Vistagen Therapeutics, Inc.'s (VTGN) pipeline across Phase 3, Phase 2. Its lead program is PH94B Nasal Spray (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Vistagen Therapeutics, Inc.'s next FDA catalyst?→
Vistagen Therapeutics, Inc.'s (VTGN) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track VTGN biotech catalysts?→
Add VTGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Vistagen Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.